Age, therapeutic "milieu" and clinical outcome in depressive patients treated with viloxazine

A study with plasma levels

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

1. 1. Authors studied 42 depressed patients of both sexes suffering from Major Depression and Dysthimic Disorder, treated with viloxazine for 4 weeks. 2. 2. All patients were divided into two groups on the basis of their age (Group 1 mean age 45 ± 2.2 and Group 2 mean age 68.3 ± 1.12). 3. 3. Viloxazine was effective in different depressive situations, regardless of the age of the patient or the therapeutic context, even if in Group 2 the out-patients did significantly better (p <0.01) than the hospitalized ones. 4. 4. Mean steady-state plasma levels and level/dose ratios were significantly higher (p <0.05) in elderly patients than in younger ones. 5. 5. No correlation between viloxazine plasma levels-clinical efficacy and side-effects was found even though patients suffering from Major Depression showed a trend to a better response with plasma levels below 5γ{phonetic}/ml. 6. 6. The satisfactory antidepressant activity and the good tolerability of viloxazine in elderly depressed patients make this drug particularly suitable for using in ambulant geriatric depressed patients.

Original languageEnglish
Pages (from-to)67-75
Number of pages9
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume10
Issue number1
DOIs
Publication statusPublished - 1986

Fingerprint

Viloxazine
Therapeutics
Phonetics
Geriatrics
Antidepressive Agents
Outpatients
Age Groups

Keywords

  • age
  • depression
  • plasma levels
  • therapeutic "milieu"
  • viloxazine

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

@article{0d6da113096c48ceb9b30aa18976a072,
title = "Age, therapeutic {"}milieu{"} and clinical outcome in depressive patients treated with viloxazine: A study with plasma levels",
abstract = "1. 1. Authors studied 42 depressed patients of both sexes suffering from Major Depression and Dysthimic Disorder, treated with viloxazine for 4 weeks. 2. 2. All patients were divided into two groups on the basis of their age (Group 1 mean age 45 ± 2.2 and Group 2 mean age 68.3 ± 1.12). 3. 3. Viloxazine was effective in different depressive situations, regardless of the age of the patient or the therapeutic context, even if in Group 2 the out-patients did significantly better (p <0.01) than the hospitalized ones. 4. 4. Mean steady-state plasma levels and level/dose ratios were significantly higher (p <0.05) in elderly patients than in younger ones. 5. 5. No correlation between viloxazine plasma levels-clinical efficacy and side-effects was found even though patients suffering from Major Depression showed a trend to a better response with plasma levels below 5γ{phonetic}/ml. 6. 6. The satisfactory antidepressant activity and the good tolerability of viloxazine in elderly depressed patients make this drug particularly suitable for using in ambulant geriatric depressed patients.",
keywords = "age, depression, plasma levels, therapeutic {"}milieu{"}, viloxazine",
author = "Altamura, {Alfredo Carlo} and Mauri, {Massimo C.} and Grazia Guercetti",
year = "1986",
doi = "10.1016/0278-5846(86)90045-X",
language = "English",
volume = "10",
pages = "67--75",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Age, therapeutic "milieu" and clinical outcome in depressive patients treated with viloxazine

T2 - A study with plasma levels

AU - Altamura, Alfredo Carlo

AU - Mauri, Massimo C.

AU - Guercetti, Grazia

PY - 1986

Y1 - 1986

N2 - 1. 1. Authors studied 42 depressed patients of both sexes suffering from Major Depression and Dysthimic Disorder, treated with viloxazine for 4 weeks. 2. 2. All patients were divided into two groups on the basis of their age (Group 1 mean age 45 ± 2.2 and Group 2 mean age 68.3 ± 1.12). 3. 3. Viloxazine was effective in different depressive situations, regardless of the age of the patient or the therapeutic context, even if in Group 2 the out-patients did significantly better (p <0.01) than the hospitalized ones. 4. 4. Mean steady-state plasma levels and level/dose ratios were significantly higher (p <0.05) in elderly patients than in younger ones. 5. 5. No correlation between viloxazine plasma levels-clinical efficacy and side-effects was found even though patients suffering from Major Depression showed a trend to a better response with plasma levels below 5γ{phonetic}/ml. 6. 6. The satisfactory antidepressant activity and the good tolerability of viloxazine in elderly depressed patients make this drug particularly suitable for using in ambulant geriatric depressed patients.

AB - 1. 1. Authors studied 42 depressed patients of both sexes suffering from Major Depression and Dysthimic Disorder, treated with viloxazine for 4 weeks. 2. 2. All patients were divided into two groups on the basis of their age (Group 1 mean age 45 ± 2.2 and Group 2 mean age 68.3 ± 1.12). 3. 3. Viloxazine was effective in different depressive situations, regardless of the age of the patient or the therapeutic context, even if in Group 2 the out-patients did significantly better (p <0.01) than the hospitalized ones. 4. 4. Mean steady-state plasma levels and level/dose ratios were significantly higher (p <0.05) in elderly patients than in younger ones. 5. 5. No correlation between viloxazine plasma levels-clinical efficacy and side-effects was found even though patients suffering from Major Depression showed a trend to a better response with plasma levels below 5γ{phonetic}/ml. 6. 6. The satisfactory antidepressant activity and the good tolerability of viloxazine in elderly depressed patients make this drug particularly suitable for using in ambulant geriatric depressed patients.

KW - age

KW - depression

KW - plasma levels

KW - therapeutic "milieu"

KW - viloxazine

UR - http://www.scopus.com/inward/record.url?scp=0022613390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022613390&partnerID=8YFLogxK

U2 - 10.1016/0278-5846(86)90045-X

DO - 10.1016/0278-5846(86)90045-X

M3 - Article

VL - 10

SP - 67

EP - 75

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 1

ER -